Find the available answers about celecoxib and supplements. Each guide explains its evidence and the forms it covers.
7 published guides. Coverage is limited to the combinations listed.
Oral willow bark preparations covered by the final EMA Salix cortex monograph, including S. purpurea, S. daphnoides and S. fragilis. The broad Willow Bark identity does not establish a product species, preparation or salicin dose.
Read the interaction guide →Oral Allium sativum supplements. The inspected trial used odor-control tablets; culinary garlic, oils and other extracts are not interchangeable.
Read the interaction guide →Oral Panax ginseng. Panax quinquefolius and other species are excluded. Red, unprocessed and extracted products cannot be treated as equivalent without characterization.
Read the interaction guide →Oral Zingiber officinale dried rhizome powder, often labeled ginger root powder. Extracts, essential oils, fresh food and mixed products are separate preparations.
Read the interaction guide →Oral Ginkgo biloba leaf preparations. Defined dry leaf extract and powdered leaf have separate monograph provisions; seeds and unrelated extracts are excluded.
Read the interaction guide →Oral supplemental potassium, with potassium chloride oral solution as the inspected salt and formulation. Elemental potassium exposure is relevant; formulation-specific doses and adverse effects are not generalized to all salts or ordinary food intake.
Read the interaction guide →This answer concerns oral celecoxib. It distinguishes mixed EPA/DHA fish oil from prescription icosapent ethyl and keeps the original studies' populations and formulations separate. Evidence does not automatically extend to ALA, DPA, krill, algal or multi-ingredient products.
Read the interaction guide →A supplement missing from this list has not been cleared for use with the medication. These pages do not assess every product, formulation, or combination.
Publication status, clinical review and change history are shown in each interaction guide.